OBJECTIVES: Sutureless and rapid-deployment valves were recently introduced into clinical practice. The Edwards INTUITY valve system is a combination of the Edwards Magna pericardial valve and a subvalvular stent-frame to enable rapid deployment. We performed a parallel cohort study for comparison of the two valve types.
INTRODUCTION
Aortic valve replacement (AVR) is one of the most common procedures in cardiovascular medicine. The range of available prostheses changed significantly during the last decades in favour of biological valve substitutes. This is partly due to the ageing patient population, which reveals excellent survival with current biological prostheses [1] . Biological valve substitutes are also increasingly implanted in younger patients due to a higher durability enabled by improved anticalcification treatment and the adverse events associated with mechanical prostheses [2] [3] [4] . A major advance in the surgical technique was the introduction of minimally invasive procedures for valve surgery [5] . Isolated AVR can be performed with minor procedural adaptations through an upper hemi-sternotomy or with advanced surgical techniques via anterior right thoracotomy (ART). However, minimally invasive AVR has been associated with longer aortic crossclamp times compared with conventional surgery due to demanding valve exposure and time-consuming suture placement [6] .
Recently, rapid-deployment biological aortic valves were approved for routine clinical use [7, 8] . These rapid-deployment systems offer several potential advantages over standard biological prostheses, including reduced procedural time and facilitated implantation in minimally invasive procedures [9] . Our centre participated in the market release trial of the Edwards INTUITY valve system, which was subsequently standardized at our department and the majority of staff surgeons was trained for valve implantation [10] . We hypothesized that the rapid-deployment valves are faster to implant and may also have a reduced transvalvular gradient due to a valve fixation system without pledgets. This hypothesis was pre-specified prior to the analysis. We report here a direct, single-centre comparison of the Edwards Magna Ease valve and its rapid-deployment successor regarding survival, reoperation rate, valve-related adverse events and echocardiographic data.
MATERIALS AND METHODS

Study population
All consecutive patients undergoing isolated AVR with either an Edwards rapid-deployment valve system (all generations) or a Carpentier-Edwards Magna Ease pericardial prosthesis (Edwards Lifesciences, Irvine, CA, USA) during the same time period starting after the introduction of the rapid-deployment valve system between May 2010 and July 2014 at a university hospital were included in this analysis. Patients receiving the rapid-deployment valve were initially included in the TRITON market release trial (Surgical Treatment of Aortic Stenosis With a Next Generation Surgical Aortic Valve, clinical trial number: NCT01445171 on http:// clinicaltrial.gov) and thereafter part of the FOUNDATION postmarket release registry (Assessing standard of care and clinical Outcomes using the EDWARDS INTUITY valve system in a European multicentre, active, post-market surveillance study, clinical trial number: NCT02338154 on http://clinicaltrial.gov). The inclusion and exclusion criteria of both trials are provided in Supplementary Material. Furthermore, 26 patients who received the rapiddeployment valve outside the TRITON or FOUNDATION trial were included in this analysis. Patients received a conventional valve as the standard of care at our department. Only some of them were contraindicated for one of the clinical trials because they either did not meet the inclusion criteria of the clinical trials or preferred having a conventional prosthesis implanted. The surgeon decided on the type of the conventional valve prosthesis based on his or her preference independent of this analysis. However, only patients receiving the Edwards Magna Ease pericardial prosthesis were included in this analysis. All patients requiring concomitant coronary bypass, valve, aortic replacement or atrial ablation surgery were excluded. Patients with root and/or annular enlargement or aortic reduction plasty were included in the analysis. Patients in TRITON and FOUNDATION were followed according to the study protocol [7] . Patients who were not part of these studies were followed in our institutional prospective INTUITY registry and in case of the conventional valve, by our institutional routine protocol.
Surgical techniques
Surgical techniques have been described previously [7] . In brief, the majority of our patients underwent 64-slice computed tomography as part of routine preoperative evaluation at our centre to identify anatomical features that may increase the risk of stroke (calcifications and soft plaques) and to determine whether the patient was suitable for the ART approach. An upper hemisternotomy incision angled into the right third intercostal space was performed in a routine fashion. ART was performed through a 7-to 8-cm skin incision at the level of the second or third intercostal space with medial detachment of the third rib from the sternum. Direct aortic and venous cannulation was favoured in minimally invasive procedures. Custodiol solution was applied in these patients for cardioplegia (Custodiol HTK, Dr Köhler Pharma, Vienna, Austria). A hockey-stick aortotomy extending into the non-coronary sinus was used to access the valve, and calcium debridement and excision of the diseased aortic valve leaflets were performed. For the INTUITY valve, three guiding sutures without pledgets placed in a 120°orientation were passed through the nadir of the aortic annulus and the corresponding part of the prosthesis' sewing ring. The INTUITY valve was deployed and its correct position confirmed under a direct vision. The delivery system was removed and the three guiding sutures were tied. Conventional valves were implanted by multiple, braided multifilament 2-0 pledgeted U-sutures by a non-everting technique. Every patient in both groups received an intraoperative transoesophageal echocardiogram prior to and after valve implantation. Patients' characteristics and risk factors were documented prospectively in the electronic data capture system of our institution (Cardiac, S2-Engineering, Steyr, Austria). Risk scores (additive and logistic EuroSCORE as well as the EuroSCORE II after its introduction) were calculated and stored. The annular diameter was measured in the subgroup of patients with a preoperative CT scan. A mean diameter was calculated out of four rectangular and diagonal measurements for each patient. Follow-up was performed in accordance with current guidelines for reporting mortality and morbidity after heart valve surgery [11] . All patients were routinely required to perform a postoperative followup visit after the rehabilitation process. Patients in a clinical study protocol were followed accordingly. In addition, all postoperative clinical contacts in public hospitals were assessed. Every patient was contacted for study purposes by telephone to complete follow-up. The follow-up time was in the range of 0-5.1 years in both groups, with a mean time of survival follow-up of 2.0 years (SD: 1.3) in the rapid-deployment AVR (RD-AVR) group and 2.9 years (SD: 1.2) in the conventional AVR (C-AVR) group (P = 0.005). The databank's closing interval was from July 2015 to August 2015 (8 weeks).
Data management
Mortality
We included all deaths after valve implantation regardless of the cause for the calculation of overall mortality. Early mortality was defined as every death during the first 30 days after the procedure. Furthermore, cardiac-and valve-related deaths were analysed. Patient survival status was also cross-checked with the countrywide database maintained by the national statistical institute (Statistics Austria, Vienna, Austria).
Morbidity
Valve-related adverse events including structural valve deterioration, non-structural valve deterioration, endocarditis, bleeding, valve thrombosis, thromboembolism (stroke, transient ischaemic attack and peripheral emboli), pacemaker implantation and myocardial infarction were assessed during follow-up according to the current guidelines [11] . Reoperations were categorized according to the underlying pathology into reoperations for structural valve disease, non-structural valve disease, valve thrombosis and endocarditis. Early surgical exploration was separated into revision for bleeding (intrathoracic bleeding or haematoma requiring re-thoracotomy or subxiphoidal drainage) and revision for myocardial ischaemia (ischaemic event leading to acute bypass surgery). Three (rapid-deployment) and nine (conventional) percent of patients were lost to follow-up for valve-related complications after the early postoperative period (P = 0.121).
Statistical analysis
Descriptive statistical methods were applied to depict the study population regarding preoperative risk factors. Continuous variables were presented as mean and standard deviation (SD) and compared by the independent samples t-test between valve types. Total numbers and proportions were reported for categorical outcomes and compared with the χ 2 test between treatment groups. The Kaplan-Meier method with a log-rank test was performed to compare survival and valve-related events. The average linearized event rates per patient year of adverse event follow-up were calculated for valve-related events. To assess a potential independent effect of the novel valve prosthesis on postoperative gradients, a multiple linear regression model was applied comprising body surface area, valve size and valve type. The residuals were inspected and there was no violation of the assumptions required for linear regression analysis. Scatterplots were added to Supplementary Material. IBM SPSS Statistics 21 (IBM Corp., Released 2012, IBM SPSS Statistics for Mac, Version 21.0, Armonk, NY, USA) was used for statistical analysis. A P-value less than 0.05 was considered as significant.
RESULTS
The study population consisted of 132 patients who underwent C-AVR and 116 patients who underwent RD-AVR. The study populations differed considerably regarding baseline characteristics, due to the inclusion and exclusion criteria of the TRITON trial and, during the early study period, the unavailability of large valve sizes for the rapid-deployment valve (Table 1) We measured the annular diameter in a subgroup of patients with a preoperative CT scan (n = 103) and were able to show a trend towards a larger annular diameter in the conventional group [24.3 mm (SD: 2.1) vs 23.7 mm (SD: 1.7); P = 0.082]. The implanted valve size showed a strong correlation with the annular diameter (Pearson's correlation coefficient 0.674; P < 0.001).
Minimally invasive procedures were significantly more common in the RD-AVR group (59 vs 39%; Fig. 1 ; P < 0.001). Overall crossclamp, cardiopulmonary bypass or procedural times were comparable between groups (Table 2) . A subgroup analysis of patients operated through a full sternotomy revealed significantly reduced aortic cross-clamp time, perfusion time and procedural time in the RD-AVR group (Table 2) . Other subgroups, periprocedural specifications and outcomes are also reported in Table 2 . A second deployment attempt was necessary in 8% of patients in the rapiddeployment group. No patient required a second pump run; however, 1 patient was reoperated due to severe paravalvular regurgitation on the day after valve implantation (non-structural valve disease; Table 3 ).
One patient died in each study group during the first 30 days (0.9% in the RD-AVR and 0.8% in the C-AVR group; P = 1.000), which was considerably below the predicted surgical risk. The long-term survival rate was, respectively, 96, 90 and 90% at 1, 3 and 5 years after surgery in the RD-AVR group, which was comparable to the C-AVR group (95, 89 and 81%; Fig. 2 ; P = 0.521). Overall, valve-related and cardiac mortality rates were 6.9% (n = 8), 3.4% (n = 4) and 4.3% (n = 5) in the RD-AVR group and 11.4% (n = 15), 6.1% (n = 8) and 6.1% (n = 8) in the C-AVR group, respectively (P = 0.226).
Although the mean implanted valve size was larger in the C-AVR group, postoperative mean gradients were comparable between groups [15 mmHg (SD: 6) in the conventional group vs 14 mmHg (SD: 5) in the rapid-deployment group; P = 0.457]. The specific distribution of valve sizes is depicted in Fig. 3 
DISCUSSION
This is the first direct comparison of a rapid-deployment biological heart valve to its conventional counterpart. One prior randomized trial (CADENCE-MIS) compared the rapid-deployment system with a range of different conventional prostheses [9] . The Edwards INTUITY valve system combines a new rapid-deployment, stent-based fixation system with an established biological valve prosthesis known for proven long-term durability [4] . Therefore, good early results are a strong predictor of excellent long-term data. Clinical data from the pre-market TRITON trial are promising [7, 10] . A special benefit in addition to the fast delivery may be a low transvalvular gradient in smaller valve sizes. The direct comparison between the two identical valve components but different anchoring mechanisms excludes potential bias regarding valve-specific leaflet tissue or commissural design. Thus, the isolated effect of the new stent-based fixation system can be evaluated and reported in vivo. Furthermore, patients with additional procedures were excluded to improve the outcome comparability. This is of specific interest in analysis of surgical access, procedural times and valve-related outcome. As previously reported, long-term survival and adverse event rates are improved for isolated AVR compared with AVR with concomitant procedures such as coronary bypass grafting because of the additional disease burden in these patients [1] . Thus, we can report two main findings from this institutional trial.
Surgical access
Minimally invasive surgical procedures were significantly more common in the rapid-deployment group. This suggests that the rapid-deployment valve system facilitates a minimally invasive surgical approach. The rapid-deployment system design was enhanced during the study period. For example, a flexible valve delivery handle became available for the later generation that further improves the ease of implantation and may increase the adoption of minimally invasive procedures. The higher ratio of minimally invasive techniques did not negatively impact the overall procedural times (Table 2) . Furthermore, we performed a subgroup analysis to compare procedural times according to surgical access. The rapid-deployment valve showed decreased cross-clamp, perfusion and procedural times in full sternotomy cases (Table 2 ). Individual subgroups with minimally invasive access were smaller and results have to be interpreted with caution. Patients with an ART had a reduced cross-clamp time (which was not significant-but only 3 patients in the C-AVR group) and also a significantly reduced perfusion time. However, cross-clamp time and perfusion time did not differ in the hemisternotomy group. We have to state that the handle of the first generation was not flexible, which was a distinct disadvantage for hemisternotomy cases. Full sternotomy allows compensation for a stiff handle and ART allows rectangular positioning of a stiff handle to the annular plane and thus parallel alignment to the outflow tract supporting an easier placement of the prosthesis, which is not the case through a hemi-sternotomy. This problem was solved with the introduction of a malleable handle. Furthermore, the learning curve with this new system is also included in the procedural times reported here. Continuous data are presented as the mean and standard deviation (SD); categorical data as total number and percentage. RD-AVR: rapid-deployment aortic valve replacement; C-AVR: conventional aortic valve replacement.
Transvalvular gradient
This study indicates that transvalvular gradients are reduced in the rapid-deployment valve. This was also suggested by previous reports. However, this is the first ever study-although limited by study design-directly comparing these two valves [9, 10] . The difference may, at first, seem counterintuitive given the identical valvular components of the Magna Ease valve and its rapid-deployment successor. But the stent-based fixation system may be the reason for a reduced transvalvular gradient. It is conceivable that the subvalvular stent-frame reshapes the left ventricular outflow tract, which may reduce turbulent flow and optimize the haemodynamic performance of the valve prosthesis. Turbulent flow and subclinical obstruction at the valve inlet may be induced by protrusion of bulky pledget material used to fixate the conventional valve or ventricular septal hypertrophy. Tabata et al. [12] previously demonstrated the negative effect of pledgeted mattress sutures on transvalvular gradients compared with single interrupted sutures. This could also be confirmed in a recent in vitro study [13] . A third potential benefit of the INTUITY valve system is that it allows the introduction of a larger valve size in a comparable annular diameter because of the recommended 'snug fit'. In contrast, when implanting a conventional valve, the surgeon may be compelled to use a smaller-sized valve in these cases or may even have to perform annular enlargement to avoid prosthesis-patient mismatch [9] . Although we were not able to confirm this hypothesis in our subgroup analysis with a rather small sample size of patients with small prosthesis and a preoperative CT scan, we will address this relevant question in a further analysis at our department.
Most periprocedural adverse events were comparable. The rapiddeployment system had a significantly reduced number of postoperative strokes. However, the rate of pacemaker implantations was increased. Patients with pre-existing bundle branch block or a preexisting AV block greater than first degree are also reported in this number, which might overestimate the valve-induced component. Surgical details during the implantation of the rapid-deployment valve may alter the positioning of the stent and by that influence the perioperative pacemaker rate. We are therefore currently examining anatomical preparations to further elucidate this question.
Limitations
This study was non-randomized and patient groups differed regarding gender, height, weight and body surface area due to inclusion/exclusion criteria of the clinical trials. The subgroup analyses performed here were not pre-specified and were performed to adjust for the differences between patient groups by applying a multiple linear regression for data interpretation.
Follow-up was more structured in the clinical studies, but a crosssectional follow-up was performed in all patients for this analysis. The sample size and follow-up time of this trial are probably not sufficient to analyse potential differences of long-term valve-related adverse events. A preoperative computed tomography was performed in the majority of patients to identify aortic calcification preoperatively. The advantages and potential drawbacks of this approach in comparison with preoperative echocardiography of the ascending aorta (when possible) or other strategies are currently under study and were not evaluated in this trial.
CONCLUSION
In conclusion, this rapid-deployment valve probably facilitates minimally invasive surgery. Furthermore, a subgroup analysis showed reduced transvalvular gradients in smaller valve sizes compared with the conventionally implanted valve of the same type. The favourable haemodynamic profile and the potentially different spectrum of valve-related adverse events should be addressed in further clinical trials.
SUPPLEMENTARY MATERIAL
Supplementary material is available at ICVTS online.
Funding
This study was not funded. However, patients from clinical trials funded by Edwards Lifesciences (Irvine, CA, USA) were included in this analysis.
